采用新型乳腺专用立体定向放疗设备对瘤床进行单次照射的前瞻性试验:GammaPod
这项前瞻性试验评估早期乳腺癌患者保乳术后采用GammaPod进行瘤床单次8 Gy推量照射的安全性和可行性,17例入组患者中14例成功完成治疗,全部放疗的急性毒性仅限于1级事件,结果促成该设备通过FDA研究性器械豁免程序获批。
要点
- 早期乳腺癌保乳术后采用GammaPod行瘤床单次8 Gy推量照射,随后1周内开始全乳放疗。
- 17例入组患者中14例成功完成GammaPod治疗,全部放疗的急性毒性仅限于1级事件。
- 该研究结果促成GammaPod通过FDA研究性器械豁免程序获得批准。
核心结论
- GammaPod设备成功对瘤床实施单次推量照射,预期急性毒性未见改变。
- 该研究结果促成该设备通过美国FDA研究性器械豁免程序获得批准。
研究设计与样本
- 前瞻性试验,评估早期乳腺癌保乳术后瘤床单次推量照射的安全性和可行性,作为该设备申请FDA批准的研究。
- 符合条件早期乳腺癌女性接受肿块切除术后放疗,采用GammaPod专用系统行乳腺固定、CT模拟定位、推量治疗计划和推量治疗均在单个治疗日内完成。
- 患者在推量治疗后1周内开始全乳放疗,评估患者和治疗的安全性与可行性并记录急性毒性。
主要发现
- 全乳放疗前对瘤床给予单次8 Gy推量照射。
- 17例入组患者中14例成功完成GammaPod治疗。
- 包括推量照射和全乳放疗在内的全部放疗急性毒性仅限于1级事件。
关键数值与推荐
- 瘤床单次推量照射剂量为8 Gy。
- GammaPod治疗成功实施于17例入组患者中的14例。
- 全部放疗的急性毒性仅限于1级事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy for early-stage breast cancer is typically delivered in a hypofractionated regimen to the whole breast followed by a tumor bed boost. This results in a treatment course of approximately 4 weeks. In this study, the tumor bed boost was delivered in a single fraction as part of a safety and feasibility study for FDA clearance of the device. METHODS AND MATERIALS: Eligible women with early-stage breast cancer underwent lumpectomy followed by radiation therapy. Patients underwent breast immobilization using a system specific to the GammaPod followed by CT simulation, boost treatment planning, and boost treatment delivery all in a single treatment day. Patients then started whole-breast radiation therapy within 1 week of the boost treatment. Patients and treatments were assessed for safety and feasibility. Acute toxicities were recorded. RESULTS: A single-fraction boost of 8 Gy was delivered to the tumor bed before a course of whole-breast radiation. The GammaPod treatment was successfully delivered to 14 of 17 enrolled patients. Acute toxicities from all radiation therapy, inclusive of the boost and whole-breast radiation, were limited to grade 1 events. CONCLUSIONS: The GammaPod device successfully delivered a single-fraction boost treatment to the tumor bed with no change in expected acute toxicities. The results of this study led to FDA clearance of the device through the Investigational Device Exemption process at the FDA. The GammaPod is in clinical use at 4e institutions nationally and internationally, with additional sites pending in 2023.
引用
- Nichols EM, Bentzen SM, Milburn M, et al. A Prospective Trial of Single-Fraction Radiation to the Tumor Bed with a Novel Breast-Specific Stereotactic Radiation Therapy Device: The GammaPod. Adv Radiat Oncol. 2024. PMID: 38778822. doi:10.1016/j.adro.2023.101398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。